Skip to content

Treatment of patients with Corona virus infection

Study the Efficacy and Safety of SeptimebTM in the Treatment of COVID-19 Infection in Iranian Patients: A Clinical Trial (Case Series)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200324046847N1
Enrollment
30
Registered
2020-03-31
Start date
2020-03-28
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection caused by COVID-19. COVID-19, virus identified’ is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing

Interventions

Intervention group: Patients who suffer from sever (ARDS patients who are not admitted in ICU) or very severe (ARDS or related symptoms and signs who are admitted in ICU) complications of COVID-19, re

Sponsors

Tehran University of Medical Sciences
Lead Sponsor
University of social welfare and rehabilitation sciences
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18-65 years Known case of Covid-19 by relative signs, symptoms, Lab. radiology and CT scan Data Existence of Severe symptoms and signs of the disease (infection by COVID-19) Not taking any immunstimulators during last three months. Completed consent form by the patients or guardians

Exclusion criteria

Exclusion criteria: Recent drug abuse or alcohol consumption. Taking growth hormone, testosterone or anabolic steroids during last 30 days. Long term use of immunosuppressives. Chemotherapy, treatment by interferon or radiotherapy during last 3 weeks• Pregnancy or breast feeding Positive symptoms for common cold or positive PCR result for influenza but not confirmed COVID-19

Design outcomes

Primary

MeasureTime frame
Number of admission days. Timepoint: every day. Method of measurement: Number of days.;The mortality rate in COVID-19 patients. Timepoint: Everyday. Method of measurement: Number of death.;Assessment of potential side effects. Timepoint: Every day. Method of measurement: Inspection for potential side effects.

Secondary

MeasureTime frame
Symptoms including coughing, fever, respiratory distress, etc. Timepoint: Every day. Method of measurement: By inspection and assessment of patients.;It is defined by the test results for: Blood gases, CBC, WBC, lymphocyte and Platelet counts; Coagulation testing; measurement of electrolytes; liver and renal function tests; CRP, LDH, Creatine kinase. Timepoint: At least every three days. Method of measurement: Measurements of Blood gases and Blood indices.;Performing radiologic and CT scan. Timepoint: At lease at the admission and discharge of patients. Method of measurement: Using radiology and CT scan equipments.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Khorram Khorshid

University of social welfare and rehabilitation sciences

hrkk1@uswr.ac.ir+98 21 2218 0138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026